Arcus Biosciences RCUS 深 沪
等待开盘 11-26 09:30:00 美东时间
24.28
+1.100
+4.75%
华盛通- 最 高24.95
- 今 开23.28
- 成交量 341.68万股
- 最 低 22.85
- 昨 收 23.18
- 总市值 25.74亿
- 52周最高 24.95
- 市盈率 静 --
- 换手率 3.22%
- 52周最低 6.50
- 委 比 -20.00%
- 总股本 1.06亿
- 历史最高 49.10
- 量 比 1.91
- 振 幅 9.06%
- 历史最低 6.30
- 每 手 1
- 风险率 3.74%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Why Keysight Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket
Shares of Keysight Technologies Inc (NYSE:KEYS) rose sharply in pre-market trad...
11-25 18:50
Arcus Biosciences prices $250M offering
Clinical-stage, global biopharmaceutical company Arcus Biosciences (RCUS) priced an underwritten public offering of 13.7M shares at $18.25 per share. Gross proceeds are expected to be $250M. The under...
10-31 12:40
美股大行评级 | 最高350美元！16家大行上调谷歌目标价！Meta遭12家大行下调目标价；潜在涨幅1456.29%！NRX Pharmaceuticals获Ascendiant Capital升目标价至47美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持NRX Pharmaceuticals"买入"评级，目标价从46美元升至47美元；富国银行：维持Kyverna Therapeutics"超配"评级，目标价从27美元升至31美元
10-31 10:25
Arcus Biosciences Announces Public Offering of Common Stock; No Size Disclosed
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, inflammatory and autoimmune
10-31 04:27
美股大行评级 | 275美元！美银证券上调英伟达目标价；花旗上调思佳讯评级至"中性"，目标价从66美元升至91美元
今日重点评级关注：HC Wainwright & Co.：维持Unicycive Therapeutics"买入"评级，目标价从9美元升至22美元；花旗：维持Arcus Biosciences"买入"评级，目标价从54美元升至56美元
10-30 14:22
Analyst Expectations For Arcus Biosciences's Future
Throughout the last three months, 5 analysts have evaluated Arcus Biosciences (...
10-29 19:45
HC Wainwright & Co. Maintains Buy on Arcus Biosciences, Raises Price Target to $28
HC Wainwright & Co. analyst Emily Bodnar maintains Arcus Biosciences (NYSE:RCUS) with a Buy and raises the price target from $24 to $28.
10-29 19:03
Arcus Biosciences Reports Promising Q3 2025 Results
Arcus Biosciences ( ($RCUS) ) has released its Q3 earnings. Here is a breakdown...
10-29 14:51
Arcus Biosciences Q3 EPS $(1.27) Beats $(1.33) Estimate, Sales $26.000M Beat $21.400M Estimate
Arcus Biosciences (NYSE:RCUS) reported quarterly losses of $(1.27) per share which beat the analyst consensus estimate of $(1.33) by 4.3 percent. This is a 27 percent decrease over losses of $(1.00) per share from the
10-29 04:39
美股大行评级 | 潜在涨幅344.44%！Rani Therapeutics获Maxim Group升目标价至10美元，维持"买入"评级
今日重点评级关注：Maxim Group：维持Rani Therapeutics Hldgs"买入"评级，目标价从5美元升至10美元；韦德布什：维持Corbus Pharmaceuticals"跑赢大市"评级，目标价从31美元升至38美元
10-21 18:13
